Viking Therapeutics Stock at $32.90 – Analysts See Potential to $101

Viking Therapeutics Inc. (VKTX) stock traded at $32.90 on July 3, 2026, up 0.61 percent from the previous day. During the trading day, the price moved between a low of $31.50 and a high of $33.95 with a trading volume of 20,069 shares.

Analysts Mostly Optimistic – Price Target at $93.60

The California-based biopharmaceutical company enjoys high regard among analysts. Of 24 recorded analyst ratings (as of July 4, 2026), 22 give a buy recommendation, and one analyst rates the stock as "strong buy." Only one hold recommendation stands against this – there are no sell recommendations.

The average price target is $93.60, with a median of $95.00. The range of analyst estimates spans from a conservative target of $83.00 to an ambitious high of $101.00. Based on the current price, this represents an upside potential of approximately 184 percent to the average target.

Technical Indicators Show Intact Upward Momentum

The Relative Strength Index (RSI) of Viking Therapeutics stock stood at 64.84 points on July 2, 2026. An RSI – a momentum indicator that measures overbought and oversold market conditions – between 30 and 70 is typically considered neutral to slightly bullish. The current value signals intact upward momentum without the stock already trading in overbought territory.

In the weeks prior, the RSI repeatedly showed values above 70, such as on June 24 with 75.03 points or on June 29 with 75.36 points. Since the end of June, the indicator has moderately cooled, suggesting healthy consolidation following a strong upward movement.

Company Background: Focus on Metabolism and Endocrine Diseases

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine diseases. The most promising candidate in its portfolio is VK2809, an orally administered, selective thyroid hormone receptor beta (TRß) agonist. The drug is currently undergoing Phase IIb trials for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Other pipeline candidates include VK5211, a non-steroidal selective androgen receptor modulator (SARM) in Phase II trials for patients following hip fractures, and VK0612, an oral drug for type 2 diabetes approaching Phase IIb trials. VK0214, another orally administered drug, is also in development.

Market Capitalization and Fundamental Metrics

At a price of $32.90 and with the existing share structure, Viking Therapeutics operates in the mid-cap segment of the biotechnology industry. As a clinical-stage development company with no approved products on the market, Viking does not yet have regular revenue streams. The valuation is therefore primarily based on the potential of pipeline candidates and progress in clinical trials.

Investors in the biotech sector typically focus on study results, regulatory milestones, and potential partnerships. The optimistic analyst ratings suggest that market observers attribute significant commercial potential to Viking's development candidates.

Trading Activity and Liquidity

The trading volume on July 3, 2026 of 20,069 shares was within the normal range for Viking Therapeutics. The difference between the daily high ($33.95) and daily low ($31.50) of $2.45 corresponds to a daily range of approximately 7.6 percent – a typical value for biotech stocks that reflects the higher volatility of this asset class.

The stock trades in USD, which represents a currency risk for investors in the DACH region. At a current exchange rate of approximately 0.93 EUR/USD, the price of $32.90 corresponds to about €30.60. Currency fluctuations can, in addition to the stock's own price movement, affect returns in euros or Swiss francs.

Outlook: Clinical Trial Results as Price Drivers

The further price development of Viking Therapeutics will likely depend significantly on the progress of its clinical programs. In particular, the Phase IIb trials of VK2809 for NASH and NAFLD – diseases with high medical need and significant market potential – are in focus. Positive interim results or successful trial conclusions could significantly boost the stock, while setbacks could have a correspondingly negative impact.

The broad support from analysts, with an average price target nearly three times the current price, reflects the expectation that at least one of the pipeline candidates will successfully reach market maturity. However, investors should be aware that biotech investments carry substantial risks – clinical trials can fail, regulatory hurdles are high, and capital commitment until potential market launch is lengthy.